双相障碍治疗结局的预测:何时可期待临床相关性?
长期药物治疗是双相障碍管理的基石,临床常通过试错选择心境稳定剂。本文综述与双相障碍长期治疗结局相关的临床特征和生物标志物,发现锂盐反应与发作性临床病程、无快速循环、低共病率、双相障碍及锂盐反应家族史、精神分裂症和重性抑郁低多基因风险相关,但临床应用仍受限。
要点
- 锂盐反应与发作性临床病程、无快速循环、低共病率相关。
- 双相障碍及锂盐反应家族史与锂盐反应相关。
- 精神分裂症和重性抑郁低多基因风险与锂盐反应相关。
核心结论
- 锂盐反应与特定临床特征及低多基因风险相关,但临床应用因疾病异质性和药物效应特异性问题未解而仍有限。
研究设计与样本
- 本文为综述,检索并总结与双相障碍长期治疗结局相关的临床特征和生物标志物研究,文献主要集中于锂盐,较少涉及丙戊酸盐和拉莫三嗪。
主要发现
- 锂盐反应与发作性临床病程、无快速循环、低共病率、双相障碍家族史及锂盐反应家族史相关。
- 锂盐反应与精神分裂症和重性抑郁的低多基因风险相关。
- 文献主要关注锂盐,对丙戊酸盐和拉莫三嗪的关注较少。
局限性
- 原文指出疾病异质性限制了这些发现的临床应用。
- 原文指出不同药物效应特异性的问题尚未解答,限制了临床应用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Long-term pharmacological treatment is the cornerstone of the management of bipolar disorder (BD). Clinicians typically select mood-stabilizing medications from among several options through trial and error. This process could be optimized by using robust predictors of treatment response. We review clinical features and biological markers studied in relation to outcome of long-term treatment of BD. To date, the literature focuses mostly on lithium and to a lesser extent on the anticonvulsants valproate and lamotrigine. The most promising results show association of lithium response with certain clinical features (episodic clinical course and absence of rapid cycling, low rates of comorbid conditions, family history of BD and lithium response) as well as low polygenic risk for schizophrenia and major depression. The clinical application of these findings remains limited, however, due to heterogeneity of the illness as well as unanswered questions about specificity of the effects of different medications.
引用
- Scott K, Khayachi A, Alda M, et al. Prediction of Treatment Outcome in Bipolar Disorder: When Can We Expect Clinical Relevance? Biol Psychiatry. 2025. PMID: 39954922. doi:10.1016/j.biopsych.2025.02.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。